FIELD: medicine.
SUBSTANCE: what is offered is a solid dosage pharmaceutical composition containing a combination of acetylsalicylic acid and ethylmethyl hydroxypyridine malate and ethylmethyl hydroxypyridine succinate possessing antiaggregant, lipid-regulating and gastroprotective activities. What is shown is substantial prolongation of shelf life of the solid dosage form.
EFFECT: pharmacological and pharmacokinetic findings of the new composition make perspective in manufacturing of the solid dosage drugs for preventing and treating obesity, pathological conditions of the cardiovascular system, preventing ischemic disorders with manifested atherosclerosis, old infarction, ischemic stroke; peripheral artery disease.
10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATION POSSESSING ANTIAGGREGANT AND LIPID-REGULATING ACTIVITIES, PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2461379C2 |
| 2-ETHYL-6-METHYL-3-HYDROXYLIRIDINIUMHYDROXYBUTANEDIOAT EXPRESSING ANTI-ISHEMIC, CEREBROPROTECTIVE, NEUROTROPIC AND LIPID-REGULATING ACTIVITY, PHARMACEUTICAL COMPOSITIONS AND MEDICAL PRODUCT | 2008 |
|
RU2377237C1 |
| ANTI-ISCHEMIC AND ANTI-ATHEROSCLEROTIC DRUG | 1998 |
|
RU2144822C1 |
| METHOD OF SYNTHESIS OF GAMMA-L-GLUTAMYLHISTAMINE, USE OF GAMMA-L-GLUTAMYLHISTAMINE, PHARMACEUTICAL COMPOSITION | 1997 |
|
RU2141968C1 |
| NOVEL 3-HYDROXYPYRIDINE DERIVATIVE HAVING LIPID REGULATING ACTIVITY | 2020 |
|
RU2743923C1 |
| ANTIHYPERLIPIDEMIC AGENT (VARIANTS) | 2002 |
|
RU2228746C1 |
| MEDICATION FOR PREVENTION AND TREATMENT OF ATHEROSLEROSIS | 2011 |
|
RU2468789C1 |
| AGENT WITH HYPOLIPIDEMIC ACTIVITY | 2004 |
|
RU2268714C1 |
| AGENT EXHIBITING HEPATOPROTECTIVE, LIPID-REGULATING, ANTIISCHEMIC AND NEUROTROPIC ACTIVITY | 2018 |
|
RU2705575C1 |
| METHOD OF PREVENTING LIPID EXCHANGE DISORDERS | 2009 |
|
RU2423123C1 |
